α5β1
Integrin, a
fibronectin receptor, is becoming a pertinent therapeutic target and a promising prognostic
biomarker for
cancer patients. The aim of this study was to functionalize an α5β1-specific
fibronectin-mimetic
peptide sequence KSSPHSRN(SG)5RGDSP (called PR_b) as a positron emission tomography (PET) probe. PR_b was modified by addition of a β-
alanine residue, conjugated with 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic
acid (p-SCN-Bn-
NOTA), and radiolabeled with (18)F based on the chelation of (18)F-aluminum
fluoride. A control probe was produced by
glycine to
alanine substitution in the RGD motif of PR_b. Cell binding and blocking assays, autoradiographic evaluation of tissue binding and blocking, dynamic PET scans, and a biodistribution study were conducted using cell lines and murine
tumor models with determined expression levels of α5β1 and other related
integrins. (18)F-PR_b was produced with a labeling yield of 22.3±1.9% based on (18)F-F(-), a radiochemical purity of >99%, and a specific activity of 30-70 GBq/µmol; it exhibited α5β1-binding activity and specificity in vitro, ex vivo, and in vivo, and had a rapid blood clearance and a predominant renal excretion pathway. In vivo α5β1-positive
tumors could be clearly visualized by (18)F-PR_b PET imaging. Both imaging and biodistribution studies suggested higher uptake of (18)F-PR_b in α5β1-positive
tumors than in α5β1-negative
tumors and higher α5β1-positive
tumor uptake of (18)F-PR_b than the control probe. In contrast, there was no significant difference seen in the contralateral muscle uptake. A PET radioprobe, (18)F-PR_b, was developed de novo and potentially can be used for noninvasive detection of α5β1 expression in
tumors.